503b workflow
7 Underrated Reasons FDA Excludes Semaglutide From 503B
A 2% cost margin can spark a $100 billion profit surge when bulk drug approvals shift from large compounding facilities to corporate manufacturing plants. The FDA excludes semaglutide from the 503B bulk list to curb unauthorized compounding and ensure consistent quality for obesity treatment. Medical Disclaimer: This article is for